1. Academic Validation
  2. Prodrug Strategy Extends the Use of Anti-HIV Sulfanylbenzamides for Application In Vivo

Prodrug Strategy Extends the Use of Anti-HIV Sulfanylbenzamides for Application In Vivo

  • ACS Pharmacol Transl Sci. 2023 Dec 14;7(1):259-273. doi: 10.1021/acsptsci.3c00260.
Marco Robello 1 Herman Nikolayevskiy 1 Michael T Scerba 1 Rogers Alberto Nahui Palomino 2 Vincenzo Mercurio 2 Daniel H Appella 1
Affiliations

Affiliations

  • 1 Synthetic Bioactive Molecules Section, Laboratory of Bioorganic Chemistry (LBC), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 8 Center Drive, Room 404, Bethesda, Maryland 20892, United States.
  • 2 Section on Intercellular Interactions, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, United States.
Abstract

Sulfanylbenzamide thioesters are molecules with anti-HIV activity that disrupt zinc coordination in the viral protein NCp7. These molecules are useful as topical microbicides; however, they are too unstable to be used systemically. In this article, a nitroimidazole prodrug was used to protect the sulfanylbenzamide to convey blood stability and oral bioavailability to the molecule. Studies on the molecule called nipamovir were performed to assess the rate of prodrug cleavage, Antiviral activity, mechanism of metabolism, and in vivo pharmacokinetics in several different species. An efficient and inexpensive synthesis of nipamovir is also described. The results indicate that nipamovir could be further developed as a new type of drug to treat HIV Infection.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-162074
    98.60%, Anti-HIV Prodrug
    HIV